BioRegenx, Inc. (BRGX)
OTCMKTS
· Delayed Price · Currency is USD
0.0108
-0.0013 (-10.74%)
Mar 5, 2026, 4:00 PM EST
BioRegenx Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 1.93 | 2.34 | 3.41 | 0.04 | 3.99 | 7.79 |
| Revenue Growth (YoY) | -24.56% | -31.40% | 7991.78% | -98.94% | -48.79% | - |
| Cost of Revenue | 0.42 | 0.68 | 1.1 | 0.05 | 1.43 | 2.06 |
| Gross Profit | 1.51 | 1.66 | 2.31 | -0.01 | 2.56 | 5.72 |
| Selling, General & Admin | 3.33 | 6.03 | 5.72 | 0.06 | 5.81 | 6.29 |
| Amortization of Goodwill & Intangibles | 0.59 | 2.18 | - | 0.01 | - | - |
| Operating Expenses | 3.92 | 8.21 | 5.72 | 0.07 | 5.81 | 6.29 |
| Operating Income | -2.41 | -6.55 | -3.41 | -0.08 | -3.25 | -0.56 |
| Interest Expense | -0.3 | -0.29 | -0.19 | - | -0.45 | -0.13 |
| Interest & Investment Income | - | - | - | - | 0.03 | 0.03 |
| EBT Excluding Unusual Items | -2.71 | -6.84 | -3.6 | -0.08 | -3.67 | -0.66 |
| Merger & Restructuring Charges | - | - | - | - | -0.01 | - |
| Impairment of Goodwill | -16.21 | -16.21 | - | - | - | - |
| Gain (Loss) on Sale of Investments | - | - | - | - | 0 | -0.12 |
| Asset Writedown | - | - | - | - | -1.11 | - |
| Other Unusual Items | - | - | - | - | 0.07 | - |
| Pretax Income | -18.93 | -23.05 | -3.6 | -0.08 | -4.72 | -0.78 |
| Net Income | -18.93 | -23.05 | -3.6 | -0.08 | -4.72 | -0.78 |
| Net Income to Common | -18.93 | -23.05 | -3.6 | -0.08 | -4.72 | -0.78 |
| Shares Outstanding (Basic) | 962 | 940 | 640 | 270 | 35 | 35 |
| Shares Outstanding (Diluted) | 962 | 940 | 640 | 270 | 35 | 35 |
| Shares Change (YoY) | 10.50% | 46.85% | 137.18% | 664.87% | 1.01% | - |
| EPS (Basic) | -0.02 | -0.02 | -0.01 | -0.00 | -0.13 | -0.02 |
| EPS (Diluted) | -0.02 | -0.02 | -0.01 | -0.00 | -0.13 | -0.02 |
| Free Cash Flow | -0.05 | -0.51 | -1.52 | -0.06 | -3.96 | -1.84 |
| Free Cash Flow Per Share | - | -0.00 | -0.00 | - | -0.11 | -0.05 |
| Gross Margin | 78.14% | 70.87% | 67.76% | -25.52% | 64.13% | 73.50% |
| Operating Margin | -125.04% | -279.93% | -99.92% | -185.74% | -81.57% | -7.22% |
| Profit Margin | -980.96% | -985.17% | -105.53% | -185.74% | -118.37% | -10.04% |
| Free Cash Flow Margin | -2.49% | -21.95% | -44.41% | -153.35% | -99.39% | -23.63% |
| EBITDA | -1.8 | -4.33 | -3.4 | -0.07 | -3.25 | - |
| EBITDA Margin | -93.34% | -185.10% | -99.78% | -174.42% | -81.55% | - |
| D&A For EBITDA | 0.61 | 2.22 | 0 | 0 | 0 | - |
| EBIT | -2.41 | -6.55 | -3.41 | -0.08 | -3.25 | -0.56 |
| EBIT Margin | -125.04% | -279.93% | -99.92% | -185.74% | -81.56% | -7.22% |
| Revenue as Reported | 1.93 | 2.34 | 3.41 | - | - | - |
| Advertising Expenses | - | - | - | 0.01 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.